Background
A 51-year-old male with primary hypertension was prescribed amlodipine/benazepril, which includes an ACE inhibitor, along with irbesartan, an ARB.
Using an ACE inhibitor and an ARB together generally provides minimal additional benefit while increasing the risk of adverse renal outcomes, hyperkalemia and hypotension.
What we did
HyperCare identified the concurrent therapy and the PharmPix clinical team evaluated it against guideline recommendations. We then contacted the prescriber and provided alternative first-line treatment options consistent with safer hypertension management.
The impact
- Supported guideline-aligned hypertension treatment
- Helped prevent avoidable renal adverse-event risk
- Reinforced safety-focused prescribing practices
Clinical protection happens at the point decisions are made. PharmPix helps identify potential medication risks and brings clinical protection to the moments that matter.
The pharmacy benefit story moves fast. Keep the whole picture in view.
The Pharmacy Benefit Brief delivers perspective on cost, policy, and member protection. One email, once a month.
The view from inside the benefit
Expert insights from pharmacists and PBM operators with an inside view of where pharmacy decisions break down, what those gaps cost, and how they affect benefit performance.
See the whole pharmacy picture.
Send us your claims data and we'll show you the avoidable cost and clinical risk hiding in it.